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Combining plasma extracellular
vesicle Let‑7b‑5p, miR‑184
and circulating miR‑22‑3p levels
for NSCLC diagnosis and drug
resistance prediction
G. P. Vadla1, B. Daghat1, N. Patterson1, V. Ahmad1, G. Perez1,4, A. Garcia1,4, Y. Manjunath2,
J. T. Kaifi2,3, G. Li2,3 & C. Y. Chabu1,2,3*
Low-dose computed tomography (LDCT) Non-Small Cell Lung (NSCLC) screening is associated with
high false-positive rates, leading to unnecessary expensive and invasive follow ups. There is a need
for minimally invasive approaches to improve the accuracy of NSCLC diagnosis. In addition, NSCLC
patients harboring sensitizing mutations in epidermal growth factor receptor EGFR (T790M, L578R)
are treated with Osimertinib, a potent tyrosine kinase inhibitor (TKI). However, nearly all patients
develop TKI resistance. The underlying mechanisms are not fully understood. Plasma extracellular
vesicle (EV) and circulating microRNA (miRNA) have been proposed as biomarkers for cancer
screening and to inform treatment decisions. However, the identification of highly sensitive and
broadly predictive core miRNA signatures remains a challenge. Also, how these systemic and diverse
miRNAs impact cancer drug response is not well understood. Using an integrative approach, we
examined plasma EV and circulating miRNA isolated from NSCLC patients versus screening controls
with a similar risk profile. We found that combining EV (Hsa-miR-184, Let-7b-5p) and circulating
(Hsa-miR-22-3p) miRNAs abundance robustly discriminates between NSCLC patients and high-risk
cancer-free controls. Further, we found that Hsa-miR-22-3p, Hsa-miR-184, and Let-7b-5p functionally
converge on WNT/βcatenin and mTOR/AKT signaling axes, known cancer therapy resistance signals.
Targeting Hsa-miR-22-3p and Hsa-miR-184 desensitized EGFR-mutated (T790M, L578R) NSCLC
cells to Osimertinib. These findings suggest that the expression levels of circulating hsa-miR-22-3p
combined with EV hsa-miR-184 and Let-7b-5p levels potentially define a core biomarker signature
for improving the accuracy of NSCLC diagnosis. Importantly, these biomarkers have the potential to
enable prospective identification of patients who are at risk of responding poorly to Osimertinib alone
but likely to benefit from Osimertinib/AKT blockade combination treatments.
Lung cancer causes the most cancer-related deaths w
 orldwide1, with 85% of lung cancer patients present with
non-small cell lung cancer (NSCLC) and 70% of the cases are diagnosed as late-stage d
 isease1–3. The 5-year survival rate for late-stage NSCLC is 2–5% compared to 92% for early-stage d
 isease1, underscoring the importance
of early detection.
Current lung cancer screening involves the use of the Lung imaging reporting and data system (Lung-RADS).
This classification system relies on chest low-dose computed tomography (LDCT) scans: based on the numbers,
size, appearance, and location of detected lung nodules, Lung-RADS assigns a score where Lung-RADS 1 means
no lung nodules, Lung-RADS 2 and 3 represent probably benign lung nodules, whereas suspicious nodules with
highest risk of cancer are categorized as Lung-RADS4.4 However, LDCT has low specificity and a high falsepositives rate (~ 23%)5. For patients who undergo multiple rounds of LDCT screening, the cumulative falsepositive rate is estimated at 38–50%5,6. In addition to the unnecessary emotional distress, these over-diagnosed
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patients are subjected to costly and invasive follow ups before they are confirmed lung cancer free. There is a
need for minimally invasive strategies that permit early and accurate detection of NSCLC.
Patients who are diagnosed with NSCLC are stratified to chemotherapy and/or immunotherapy, or targeted therapy based on the presence or absence of known NSCLC driver mutations in tissue biopsy a nalyses7,8.
Depending on patients’ ethnicity, activating mutations of epidermal growth factor receptor (EGFR) tyrosine
kinase is found in 15–50% of N
 SCLC9–11. Patients harboring drug sensitizing EGFR mutations are treated with
tyrosine kinase inhibitors or TKI. Some patients initially respond to tyrosine kinase inhibitors (TKI) but ultimately develop resistance: cancers acquire TKI-desensitizing EGFR mutations or activate compensatory signals,
including WNT/β-catenin, the mechanistic target of rapamycin mTOR, and AKT signaling to drive cancer
recurrence12–20. Screening for genetic alterations that activate these signaling pathways provides a rationale
for prioritizing treatment options that maximize the probability of achieving durable outcomes. However, it is
becoming increasingly evident that cancer cells develop drug resistance via complex non-mutational mechanisms
that involve emergent cell–cell interactions mediated by microRNAs (miRNAs)21–24. miRNAs are short (19–23)
non-coding nucleotides that degrade protein transcripts and fundamentally impact signaling e vents25–27. These
miRNAs are released directly into the blood circulation (circulating miRNA) or secreted as extracellular vesicles
(EV) cargo to elicit signaling events in target cells28,29. The potential for EV miRNA as minimally-invasive liquid
biomarkers is now widely r ecognized30,31.
In this study, we integrated EV and circulating blood miRNA analyses to identify combined EV and miRNA
features that robustly differentiate cancer patients from disease-free controls. Further, the identified miRNAs
converge on WNT/β-catenin and AKT/mTOR signaling pathways, suggesting a role in drug-resistance and
highlighting their potential as biomarkers for predicting therapy response and for selecting patients that will
likely benefit from AKT blockade.

Results

CD9 and CD63, but not CD81, are enriched on NSCLC patients extracellular vesicles. There is

a critical need for sensitive, robust, and minimally-invasive tools for improving the accuracy of NSCLC diagnosis. To this end, we interrogated plasma extracellular vesicles and miRNA to identify molecular signatures that
can discriminate between NSCLC patients and healthy individuals with similar risk profiles. The US Preventive
Services Task Force recommends LDCT screening for at-risk individuals defined as 55–80 years of age with 30
or more pack-year smoking history or have quit within the past 15 years32. Individuals ranging between 42 and
62 years of age with a qualifying smoking history were divided into two groups based on their initial LDCT
Lung-RADS scores 2 or 4 (Table 1, Lung-RADS2 screening controls versus Lung-RADS4, N = 20 per group).
We isolated plasma EV from all 40 individuals (Fig. 1a) and performed nanoparticle tracking analyses (NTA)
to determine whether EV from Lung-RADS4 patients cohort exhibit physical characteristics that are distinct from
control cohort EV. Initial analyses revealed that EV density was reduced in Lung-RADS4 patients compared to
screening controls but these EV were larger than Lung-RADS2 EV (Fig. 1b,c).
LDCT has a false positive rate of 23–50%5,6,33. Consistent with this, follow up tissue biopsies analyses revealed
that 30% (6 out of 20) of the patients who were classified as Lung-RADS4 at baseline LDCT screening did not
have lung cancer (Table 1; group column, asterisk). We asked whether the EV density and size characteristics
can differentiate between true Lung-RADS4 patients with lung cancer and the rest of the patients with benign
lung nodules without cancers (Lung-RADS2 plus the false-positive Lung-RADS4 patients). Although the trend
of reduced EV density and larger EV size in true Lung-RADS4 compared to controls persisted, these differences
were not statistically significant (data not shown).
We then asked whether EV membranes molecular profiles can differentiate between screening controls, overdiagnosed individuals, and confirmed cancer patients. We first examined the protein abundance of known EV
membrane markers (the tetraspanins CD9, CD63, CD81, and the resident EV protein flotillin). While EV isolated
from all Lung-RADS4 (initial diagnosis, including false-positive) patients and screening controls showed similar
levels of CD81 and flotillin, CD63 and, to a lesser extent, CD9 were specifically enriched in Lung-RADS4 EV
(CD63 high, CD9 moderate) compared to Lung-RADS2 screening controls (CD63 low and CD9 low) (Fig. 1d
and Supplementary Information 3). EV exclusively derived from confirmed NSCLC patients ( IV+) were CD63
high and CD9 moderate) when compared to EV from false-positive patients (CD63 low and CD9 moderate) or
to screening controls (II: CD63 low and CD9 low) (Fig. 1e–g and Supplementary Information 3). Consistent with
these findings, the ratio of CD9/CD63 levels distinguished confirmed cases from false-positive Lung-RADS4
or screening individuals [Fig. 1h, (mean ± SD): 0.37 ± 0.1 vs. 1.86 ± 0.66 vs. 5.08 ± 1.48, respectively). Thus, EV
CD9/CD63 expression ratio, but not EV physical characteristics, may help differentiate NSCLC patients from
cancer-free high-risk individuals.

Plasma Let‑7b‑5p, miR‑184, and miR‑22‑3p levels differentiate NSCLC patients from high‑risk
individuals. Next, we used next generation sequencing (NGS) approaches to profile EV miRNAs from Lung-

RADS4 confirmed cancer patients or over-diagnosed Lung-RADS4 individuals or high-risk screening controls
(Lung-RADS2). We included circulating plasma miRNA because combining multiple analytes from diverse
biological sources have the potential to identify robust biomarkers. We identified 58 differentially expressed
miRNAs, including miRNAs widely known to be deregulated in cancers (Supplemental Table 1). To identify
a set of miRNAs that can robustly discriminate between NSCLC and cancer-free individuals, we prioritized
miRNAs that were differentially expressed in at least two of the following comparisons: Lung-RADS2 versus
Lung-RADS4; Lung-RADS4 false positive versus confirmed cancer patients; Lung-RADS2 combined with falsepositive Lung-RADS4 patients versus confirmed cancer patients; any of the preceding groups versus patients
who rapidly progressed (LDCT imaging and/or death shortly after sampling). We then focused on miRNAs
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Lung-RAD
Score
Sample ID

Age (years, as of 2019)

Gender

82

62

M

Smoking history (pack—year) Group
40

A

Initial

latest

Death Cancer Related

2

4A

None

83

64

F

40

A

2

2

None

84

62

F

45

A

2

2

None

85

62

F

30

A

2

2

None

88

45

F

80

A

2

2

None

91

51

F

40

A

2

2

None

96

58

F

45

A

2

2

None

98

56

F

45

A

2

2

None

99

60

M

35

A

2

2

None

100

61

F

30

A

2

4A

None

102

53

F

40

A

2

2

None

104

58

M

50

A

2

2

None

105

53

F

80

A

2

2

None

106

48

M

45

A

2

2

None

111

57

F

60

A

2

2

None

114

61

M

30

A

2

3

None

120

63

F

40

A

2

4A

None

121

57

F

90

A

2

3

None

123

50

F

40

A

2

2

None

124

61

M

50

A

2

2

None

8

50

F

100

B

4

4B

None

12

50

F

55

B

4

4X

None

15

56

F

45

B

4

4B

None

16

42

F

40

B

4

4B

None

30

49

F

55

B

4

4A

Yes

40

55

M

45

B*

4

4B

None

52

44

F

50

B

4

4B

None

53

58

M

27

B

4

4B

None

70

45

M

50

B

4

4X

None

92

61

M

40

B*

4

4A

None

115

51

F

40

B

4

4B

None

135

50

M

25

B*

4

4B/4X

None

138

49

F

100

B

4

4X

Yes

139

52

F

40

B*

4

4A

None

149

57

M

40

B*

4

4B

None

152

49

F

25

B

4

4B

None

159

60

M

60

B

4

4B

None

170

53

F

40

B

4

4B

None

171

55

M

80

B*

4

2

None

183

56

F

40

B

4

4X

None

Table 1.  Study participants. Table showing each patient’s description including, age, gender, smoking history,
and cancer progression status. False positive diagnoses are denoted with an asterisk (*) in the Group column.
Group A and B contain individuals with lung-RADS2 or lung-RADS4 initial LDCT findings, respectively.

showing significant performance (P and area under the curve/AUC values) in receiver operating characteristic
(ROC) analyses for further examination. This approach led to the discovery of let-7b-5p, miR-184, and miR22-3p as potential biomarkers for discriminating cancer patients from high-risk controls.
Let-7b-5p levels were elevated in EV from Lung-RADS4 patients compared to EV from screening patients
alone (Fig. 2a,e) or to screening patients plus false-positive Lung-RADS4 patients combined (Fig. 2b,f). Also,
miR-184 abundance was significantly reduced in Lung-RADS4 EV compared to either control group (excluding
or including false-positive Lung-RADS4 patients) (Fig. 2c,d,g,h). Circulating miRNAs analyses showed that miR22-3p levels were reduced in Lung-RADS4 patients compared to either control group (Fig. 2i–l). ROC curves
showed area under the curve (AUC) values above 70% and significant p values for all of the identified markers
across comparisons (Fig. 2e–h,k,l). The expression of these miRNAs was independently verified in quantitative polymerase chain reaction (qPCR) experiments using EV or plasma samples obtained from controls or
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Figure 1.  CD9 and CD63, but not CD81, are enriched on NSCLC EV. (a) Representative transmission electron
micrograph of the isolated extracellular vesicles (EV). (b,c) Nanoparticle tracking analyses (NTA) data showing
EV concentrations (particles/mL) (b) and size distribution (c). One-way ANOVA analysis was performed to
determine statistical significance, *< 0.05. (d) Western blot image showing abundance of EV markers (CD81,
CD63, CD9, and Flotillin) in EV isolated from blood samples obtained from screening controls (LNG-RADS
II) or LNG-RADS IV individuals. (e) Western blot images from triplicate samples showing CD9 and CD63
protein levels in EV extracted from LNG RADS II or confirmed cancer patients ( IV+) plasma or disease-free
LNG-RADS IV (IV−) individuals. Flotillin protein levels are used as loading controls. These experiments are
shown in triplicates. (f,g) Relative quantification of CD9 and CD63 protein levels in Western blot shown in (e).
Proteins levels are denoted as ratio of pixel intensities mean values quantified from each of the three replicates
and normalized to Flotillin. (h) Ratio of CD9:CD63 protein band intensities presented in (e). Quantification
of band intensities (pixels) was performed using ImageJ. Bars represent data as mean ± SD. p values are derived
from t-test. *p < 0.05, **p < 0.01, ***p < 0.001.
false-positives or confirmed cancer patients (Fig. 2n–p and Supplemental Fig. 1a–c). Further, the expression of
Let-7b-5p, miR-184, miR-22-3p showed no significant correlation with the gender, age, and pack-years smoking record of the participants (Supplemental Fig. 1d and Supplemental Table 1), providing additional statistical
rigor and indicating that the expression profile of these EV and circulating miRNAs is specifically associated
with disease status.
Moreover, multiple logistic regression analyses of let-7b-5p, miR-184, and miR-22-3p showed a combined
ROC AUC value of 92.4% (p < 0.0001, Fig. 2m and Supplemental Table 2). Furthermore, leave-one-out cross
validation (LOOCV) analyses of the three predictor microRNAs (let-7b-5p, miR-184, miR-22-3p) showed an 80%
match between the prediction and the outcome (Supplemental Table 4). Taken together, the above data indicate
that these combined analytes (EV let-7b-5p, miR-184 levels combined with circulating miR-22-3p levels) robustly
differentiate cancer patients from high-risk controls.

Let‑7b‑5p, miR‑184, and miR‑22‑3p converge on treatment‑resistance mechanisms. We con-

sidered the possibility that these EV and circulating plasma miRNAs (let-7b-5p, miR-184, and miR-22-3p) mediate cell–cell communication events that support NSCLC disease progression. First, we used the miRNA target
proteins analysis platform MIRNET to identify experimentally validated protein targets of let-7b-5p, miR-184,
and miR-22-3p. We prioritized proteins that are targeted by at least two of the three miRNAs from experimental
data (MIRNET miR2gene)34. This approach identified 43 proteins (Fig. 3a and Supplemental Table 3), which
were subsequently interrogated in Gene Ontology analyses using Kyoto Encyclopedia of Genes and Genomes
(KEGG) or Reactome classifications to derive signaling pathways. Cancer was the most highly enriched KEGG
term (Fig. 3b,c), underscoring the robustness of our experimental pipeline and the relevance of these miRNAs
to cancer disease. Interestingly, KEGG and Reactome signaling maps revealed that let-7b-5p, miR-184, and miR22-3p converge on the activation of WNT and PI3K-AKT-mTOR signaling (Fig. 3c,d), suggesting that circulating and EV miRNAs cooperatively regulate WNT and PI3K-AKT-mTOR activity in NSCLC. Activation of WNT
or PI3K-AKT-mTOR signaling in NSCLC tissues is associated with aggressive and therapy resistant disease35,36.
Considering that miR-184 and miR-22-3p are downregulated in cancer patients, this suggests that plasma from
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Figure 2.  Identification of unique EV and circulating miRNA profiles Lung-RADS4 cancer patients. (a-l)
Next Generation Sequencing (NGS) of blood EV or circulating miRNA identified Let-7b-5p, miR-184, and
miR-22-3p as differentially expressed in NSCLC patients compared to controls. Let-7b-5p (a,b) and mir-184
(c,d) are deregulated in EV and mir-22-3p in plasma (i,j). The relative abundance of the indicated miRNA in
screening controls (blue) versus confirmed diseased patients only (green) or versus all lung-RADS2 plus falsepositive lung-RADS4 (magenta) are shown in (a–d) and (i,j), respectively. P values were Benjamini–Hochberg
adjusted. *p < 0.1, **p < 0.05, ***p < 0.01, ****p < 0.001. Note that 2–3 patient samples with undetectably low reads
were excluded from the analysis. Corresponding Reads per million (RPM) were used to plot miRNA levels in
confirmed cancer patients versus disease-free individuals and to perform ROC analysis shown in (e–h,k,l).
EdgeR generalized linear models (GLM) were used to assess significance of miRNA regulations. Multiple logistic
regression analysis was performed to determine the combined classification performance of the three miRNA
biomarker candidates (m). Statistical significance of miRNA regulations was determined by EdgeR GLM, as
indicated above. (n–p) Quantitative Polymerase Chain Reaction (qPCR) data showing expression fold changes
(means) of let-7b-5p (n) or miRNA-184 (o) or miRNA-21-5p (n) or miRNA-22-3p (p) in EV samples obtained
from confirmed cancer patients (IV +) versus screening controls (II). RNA samples were pooled from 14 cancer
patients and 14 randomly selected screening individuals. Expression was normalized to GAPDH. Error bars
denote SD values. P values are derived from student t-test analyses.

Scientific Reports |

(2022) 12:6693 |

https://doi.org/10.1038/s41598-022-10598-x

5
Vol.:(0123456789)

www.nature.com/scientificreports/

Figure 3.  Let-7b-5p, miR-184, and miR-22-3p converge on AKT/mTOR and WNT/β-catenin therapy resistance pathways. (a) Venn
diagram showing the number unique of shared protein targets between the selected miRNAs. (b) MIRNET star-network showing
proteins that are targeted by at least two of the three miRNAs (blue squares). (c,d) KEGG (c) or Reactome (d) classification analyses of
the identified proteins show a convergence onto PI3K-AKT-mTOR (c, magenta label and d green label) and WNT/β-catenin (d, brown
label) signaling pathways. The underlying target genes are shown in corresponding color in “b”. (e) Western blot image from A549
cells treated with equal quantity of EV from cancer patients or from high-risk screening controls. Blots were stained against β-catenin
to detect WNT signaling levels or GAPDH as a loading control. (f,g) Western blot images from A549 cells cultured in standard media
or media conditioned with PBMC in the absence or presence of patients EV (f, lanes 1–4). Also, A549 cells were treated directly with
cancer patients or control EV (f, lanes 5 and 6). Blots were stained against phospho-AKT1 (f) or phospho-mTOR (g) or GAPDH as a
loading control (f,g). A549 cell numbers from supernatant transfer experiments (f, lanes 1–4) are shown in “h” as average cell numbers
from triplicate experiments. Error bars denote SD values. P values are derived from student t-test analyses. (i,j) qPCR data showing
mean expression fold changes of miR-184 (i) or miR-22-3p (j) in H1975 cells transfected with miR-184 (i) or miR-22-3p inhibitors
(j) (blue bars) compared to untreated H1975 control cells (red bars). Expression was normalized to GAPDH. (k) Western blot images
from H1975 cells left untreated or treated with miR-22-3p or miR-184 inhibitors and blotted against phospho-AKT1 or GAPDH
(loading control). (l) Image of a Western blot from untreated H1975 cells or H1975 cells treated with equal portions of EV from
screening controls (RADS-II) or with inhibitors against miR-22-3p and/or miR-184 inhibitors followed with Osimertinib (100 nM)
treatments. Western blots were stained against phospho-AKT or GAPDH (loading control). (m) Graph showing the proportion
of H1975 cell death across the indicated conditions using Trypan blue exclusion assays. These cell death assays were performed in
triplicates and the results are shown as the average proportion (percentage) of dead cell across replicates for each treatment conditions.
Error bars denote standard deviations and p values were derived from t-tests. (n–p) Survivorship comparison data using miR-184 and/
or miR-22-3p expression data in TCGA-LUAD and the Bioconductor tool TCGA Biolinks RTCGA R packages. The “surv_cutpoint”
function of the “survminer” R package was used to identify high versus low expressing patients’ samples for miR-22-3p (n) or miR-184
(o) or both (p) in Cox regression analyses. Survminer uses selected rank statistics to determine the optimal cut-point of a continuous
variable in an unbiased manner. The related bioinformatics and statistics are presented in Supplementary Information 1. (q,r)
proposed model summarizing the role of mir-184/mir-22 in Osimertinib drug response. EV (mir-184) and circulating (mir-22) plasma
miRNAs cooperatively target and modulate AKT activity. (q) Cancer-free high-risk individuals up-regulate EV mir-184 and circulating
mir-22, keeping AKT levels generally low. In the context of genetic driver mutations, this low AKT activity delays oncogenesis.
Similarly, cancer patients with high EV mir-184 and circulating mir-22-3p maintain AKT below an activity threshold required for
AKT-mediated drug resistance, leading to positive drug response. However, AKT baseline activity is elevated in patients with low
mir-184/mir-22 levels such that even a modest stimulation of AKT drives AKT above the drug-resistance activity threshold, leading to
relapses and poor clinical response (r).
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high-risk, yet cancer-free individuals contain EV and circulating miRNAs that suppress WNT and the AKT
signaling axis and that these mechanisms are restrained in NSCLC patients.
Indeed, treatment of NSCLC cells (A549) with cancer patients EV elevated WNT and AKT signaling levels
compared to the effect of EV from screening controls, as determined by β-catenin and phospho-AKT protein
levels, respectively (Fig. 3e,f, and Supplementary Information 3).
Further, the uptake of EV by immune cells results in paracrine signaling loops that ultimately accelerate
disease progression via complex mechanisms37–39. We performed supernatant transfer experiments and asked
whether cancer patients EV stimulate AKT/mTOR in A549 cells either directly or via immune cells. A549 cells
were cultured in media conditioned by peripheral blood mononuclear cells (PBMC) left untreated or treated
with EV either from controls or from cancer patients. Cancer patients EV/PBMC media dramatically stimulated
phospho-AKT and phospho-mTOR levels in A549 cells, compared to controls (Fig. 3f,g, and Supplementary
Information 3). Note that EV from the high-risk controls also stimulated mTOR, possibly reflecting a NSCLC
priming state (see “Discussion”). Consistent with this AKT/mTOR stimulating potential, EV/PBMC conditioned
media accelerated the growth of A549 cells (Fig. 3h). Taken together, the above data argue that plasma EV act
directly or via immune cells to activate AKT in NSCLC.
Next, we sought to determine whether let-7b-5p, miR-184, and miR-22-3p mediate the AKT activating effect
of cancer EV and what implication this might have on NSCLC treatment outcomes. Activating mutations in
Epidermal Growth Factor Receptor (EGFR) signaling represent one of the most known genetic alterations associated with N
 SCLC40,41. Patients harboring sensitizing EGFR mutations (exon 19 deletion and L858R) respond
favorably to first- and second-generation Tyrosine Kinase Inhibitors/TKI (gefitinib, erlotinib, afatinib, and dacomitinib). However, patients acquire TKI-desensitizing EGFR mutations (T790M) and become resistant to these
TKIs. Osimertinib, a third generation TKI selectively targets EGFR T790M and generates significant clinical
benefits in EGFR T790M patients10,42–45. Unfortunately, all patients ultimately develop resistance to Osimertinib
because they acquire an Osimertinib-desensitizing mutation (C797S) or activate complex compensatory signals
to resist drug-induced cell death and to promote cancer cell p
 roliferation15,46–48. Understanding the nature of
these signals and how they are activated have the potential to inform new treatment strategies for re-sensitizing
patients to existing TKIs.
We investigated a role for let-7b-5p, miR-184, and miR-22-3p in NSCLC response to Osimertinib using H1975
NSCLC cells, which harbor L858R and T790M EGFR mutations. First, H1975 cells were transfected with miR-184
and miR-22-3p inhibitors, mimicking their reduction in cancer patient plasma. We then assessed the effect of
miR-184/miR-22-3p inhibition on AKT activity. The inhibitors reduced miR-184 and miR-22-3p levels in qPCR
assays (Fig. 3i,j, respectively) and cooperatively elevated pAKT levels in H1975 cells (Fig. 3k,l, Supplementary
Fig. 2, and Supplementary Information 3).
In reciprocal experiments we found that Lung-RADS2 EV, which overexpress miR-184 (Fig. 2c,o), inhibit
Osimertinib-induced AKT activity in H1975 cells (Fig. 3l and Supplementary Fig. 2). Importantly, inhibition of
miR-22-3p in this setting was sufficient to dramatically unleash AKT (Fig. 3l and Supplementary Fig. 2), further
highlighting the cooperation between these two miRNAs in modulating AKT activity. Finaly, we investigated
the effect of miR-184/miR-22-3p inhibition on Osimertinib-induced cell death. Consistent with AKT stimulation, miR-184/miR-22-3p inhibition significantly suppressed Osimertinib-induced cell death (Fig. 3m). Similar
results were observed when miR-184/miR-22-3p co-inhibited cells were treated in the presence of a let-7b-5p
mimic (Fig. 3m).
AKT activation is associated with NSCLC resistance to TKI, leading to reduced patient survival time35,36.
Thus, we sought to determine to what extent reduced miR-184/miR-22-3p tumor expression correlates with
reduced patient survival using the cancer genome atlas (TCGA) LUAD patient tumor miRNA expression and
survival data. Let-7 could not be combined with miR-22 or miR-184. Only a small number of patients (12) in
the LUAD TCGA had combined expression data for Let-7 and miR-22/miR-184, making it difficult to reliably
perform the analysis.
We did not detect any significant survival difference between patients whose tumors express low miR-22-3p
(Fig. 3n). However, patients with low miR-184 tumor expression had a significantly shorter survival time compared to patients with higher miR-184 tumor expression (Fig. 3o, Hazard Ratio 2.09, 95% CI: 1.13, 3.84, p < 0.018).
Interestingly, patients with miR-184/miR-22-3p co-repressed tumors experienced even shorter survival time
compared to patients with high miR-184/miR-22-3p tumor expression (Fig. 3p, Hazard Ratio 3.43, 95% CI: 1.26,
9.32, p < 0.016). Note that the survivorship of miR-184/miR-22-3p tumor low patients is significantly lower than
that of patients with tumor low miR-184 alone or miR-22-3p alone. This is consistent with AKT activation in
miR-184/miR-22-3p co-inhibited NSCLC patients’ plasma and treatment resistance.
Thus, EV (let-7b-5p, miR-184) and circulating (miR-22-3p) plasma miRNA likely modulate NSCLC response
to Osimertinib, highlighting a novel mechanism of resistance and suggesting that these biomarkers may assist
in the selection of patients that will likely benefit from Osimertinib/AKT blockade combination treatments.

Discussion

The implementation of LDCT in NSCLC screening has reduced patient deaths by ~ 20%5. However, LDCT screening has a 23–50% false-positive rate5,6,33, causing unnecessary exposure to radiation, costly and invasive follow-up
studies for these mis-diagnosed patients. Additional strategies are needed to improve NSCLC screening accuracy.
Here we report the identification of a set of miRNAs (let-7-5p, miR-184 from EV and miR-22-3p from circulating miRNAs) that distinguishes NSCLC patients from high-risk controls. In addition, we found that the
EV markers CD9, CD63, but not CD81 or flotillin, are differentially expressed in NSCLC patients compared to
high-risk controls.
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Some of the unique features of this study include the fact that reference and disease cohorts were controlled
for risk profiles, reducing noise, and elevating the relevance of the identified biomarkers in NSCLC. Also, circulating miRNA are gaining much interest as potential biomarkers in lung c ancer30,31. Different from others, our
study integrates plasma and EV miRNAs to not only identify potential core molecular signatures for NSCLC
risk management but to also highlight a plausible cooperation between these miRNAs in influencing patients’
drug response. Combining multiple analytes of diverse biological origins (EV surface markers, EV, and plasma
miRNAs) also maximizes robustness in diagnostics. Consistent with this, our biomarkers were able to differentiate confirmed NSCLC patients from LDCT false-positives, suggesting that addition of these non-invasive
biomarkers to LDCT screening has the potential to improve diagnosis accuracy.
Confirmed NSCLC patients are stratified to diverse treatment options, including chemotherapy, immunotherapy, and targeted therapies based on histological and genetic mutations profiles obtained from tissue biopsies.
Due to positional constraints, however, tissues biopsies often fail to capture the broader complexity of genetic
driver mutations, leading to incomplete targeted therapy responses. The profiling of cancer-derived EV from
patients’ plasma may provide deeper insights into the overall cancer mutational landscape of the tumor and thus
better guide treatment decisions in the future. Indeed, pathway analyses of let-7b-5p, miR-184, and miR-22-3p
target proteins revealed that these miRNAs converge on therapy resistance signals, including AKT. We propose
that circulating and EV miRNAs functionally cooperate to modulate oncogenesis or patients’ clinical outcomes
(Fig. 3q, r). The AKT-suppressing miRNAs miR-184/miR-22-3p function as tumor suppressors and delay oncogenesis (Fig. 3q). Cancers downregulate the expression of these miRNAs and/or reduce their systemic abundance
via an unknown mechanism, leading to high baseline AKT activity and potentially resulting into accelerated
cancer growth and drug resistance (Fig. 3r). Depending on context, EV and plasma miRNAs may act directly or
via tumor-interacting immune components to modulate mTOR/AKT total protein levels or activity state (i.e., by
downregulating upstream regulators of mTOR/AKT), thereby influencing tumor cell behavior. Congruent with
these possible modes of action, targeting miR-184 or miR-22-3p moderately elevated total mTOR protein levels
in A549 cells (Supplementary Fig. 2b). However, these treatments show no detectable effect on total AKT levels
but dramatically increased phospho-AKT levels in H1975 cells (Supplementary Fig. 2a and Fig. 3k,l).
Mimicking the expression profile of miR-184 (EV) and miR-22-3p (plasma) in NSCLC patients’ blood using
miRNA inhibitors cooperatively activated AKT and desensitized NSCLC cells (H1975) to Osimertinib. Thus,
Let-7b-5p, miR-184, and miR-22-3p represent liquid biopsy biomarkers that will potentially assist with the
identification of patients that will likely benefit from Osimertinib/AKT blockade combination treatments. AKT
inhibition re-sensitizes TKI-resistant NSCLC cells to erlotinib and g efitinib49. A clinical trial evaluating the
efficacy of combining Osimertinib with aspirin (an AKT inhibitor) in advanced NSCLC patients is pending
(NCT04184921). Further, aberrant activation of AKT/mTOR and WNT/β-catenin signaling are associated with
therapy resistance across different cancer types, suggesting broad translatability for these markers and their
underlying mechanisms of action.
One limitation for this study is the limited size of the discovery cohorts (cases and controls). Future validation studies will include determining to what extent blood levels of Let-7b-5p, miR-184, and miR-22-3p detect
NSCLC and predict disease relapse in larger patient cohorts.
We noted that EV derived from high-risk control patients elevated mTOR levels in A549 cells. We cannot
rule out the possibility that this EV-induced mTOR activation is specific to A549 cells, but it is possible that this
effect reflects a priming state that precedes NSCLC onset in these high-risk patients.
Finaly, the observation that circulating and EV miRNAs that suppress cancer cell survival and growth signals are upregulated in blood from high-risk cancer-free individuals compared to cancer patients also provides
insights into why, despite having comparable NSCLC risk profiles, some individuals do not develop cancer, but
others do.

Ethical considerations. All blood samples were collected with participants’ written informed consent and
in compliance with the University of Missouri ethical guidelines. The protocol was approved by the University of
Missouri Ethics committee (IRB approval #2010166).

Materials and methods

Isolation of extracellular vesicles and circulating micro‑RNA. Patients’ blood was double-centrifuged to remove platelets and the platelet-poor plasma was used for EV analysis. Purification of the EVs was
done through size exclusion chromatography (SEC) using qEV70s single columns (ddIzon, Netherlands). These
columns were filled with 150 µL of plasma and used based on recommendations from the manufacturer; fraction
8 through 11 were collected and pooled to obtain the fraction of purified EVs. The particle size and concentration for all EV samples were determined using nanoparticle tracking analysis (NTA).
Total RNA extraction was performed as previously described50 using 200 µL of plasma or 200 µL of pooled
EV fractions and the miRNeasy mini kit (Qiagen). Samples were thawed at room temperature followed by centrifugation at 12,000×g for 5 min at 4 °C to remove any debris. Extraction was conducted by use of the miRNA
easy Qiagen kit. For homogenization, 200 µL of plasma/EV suspension were mixed with 1000 µL Qiazol and 1 µL
of a mix of 3 synthetic spike-in controls (Qiagen, Germany). After a 10-min incubation at room temperature,
200 µL chloroform were added to the lysates followed by cooled centrifugation at 12,000×g for 15 min at 4 °C.
Precisely 650 µL of the upper aqueous phase were mixed with 7 µL glycogen (50 mg/mL) to enhance precipitation.
Samples were transferred to a miRNeasy mini column, and RNA was precipitated with 750 µL ethanol followed
by automated washing with RPE and RWT buffer in a QiaCube liquid handling robot. Finally, total RNA was
eluted in 30 µL nuclease free water and stored at − 80 °C until further use.

Scientific Reports |
Vol:.(1234567890)

(2022) 12:6693 |

https://doi.org/10.1038/s41598-022-10598-x

8

www.nature.com/scientificreports/
Electron microscopy.

Exosomes were processed for negative staining as described in Rames et al.51. Briefly,
5 µL of purified EV sample was applied to a freshly glow discharged (Pelco Easiglow, Ted Pella Redding CA)
carbon coated TEM grid (Electron Microscopy Sciences, Hatfield PA) over ice. Samples were washed three times
with distilled water, incubated 2 min on 2% paraformaldehyde (Electron Microscopy Sciences), then incubated
for 30 s on 2% uranyl acetate (aqueous, Electron Microscopy Sciences) and back-blotted with filter paper (Whatman P1, Fisher Scientific) and allowed to dry. Images were collected on a JEOL JEM 1400 transmission electron
microscope operated at 120 V equipped with a Gatan Ultrascan 1000 CCD camera.

Small RNA sequencing. Small RNA sequencing was performed as described p reviously52. Equal volumes

of total RNA (2 µL) were used for small RNA library preparation using the Clean Tag small RNA library preparation kit (TriLink Biotechnologies, US). That utilizes chemically modified adapters to prevent formation of
adapter dimers53. Adapter-ligated libraries were amplified using barcoded Illumina reverse primers in combination with the Illumina forward primer. A pool consisting of 40 plasma samples, and a second pool consisting of 40 EV samples was prepared by mixing samples at equimolar rates based on a DNA-1000 bioanalyzer
results (Agilent, CA). The DNA library pool underwent size-selection (BluePippin, SageScience, US) to enrich
for microRNAs with an insert size of 18–36 nt, corresponding to a library size of approximately 145 bp.
Sequencing was performed on an Illumina NextSeq 550 with 75 bp single end runs. Overall quality of the
next-generation sequencing data was evaluated automatically and manually with FastQC v0.11.8 and MultiQC
v1.7. Reads from all passing samples were adapter trimmed and quality filtered using Cutadapt v2.3 and filtered
for a minimum length of 17nt. Mapping steps were performed with bowtie v1.2.2 and miRDeep2 v2.0.1.2,
whereas reads were mapped first against the genomic reference GRCh38.p12 provided by Ensemble allowing for
two mismatches and subsequently miRBase v22.1, filtered for miRNAs of hsa only, allowing for one mismatch.
For a general RNA composition overview, non-miRNA mapped reads were mapped against RNAcentral and
then assigned to various RNA species of interest.
Statistical analysis of preprocessed NGS data was done with R v3.6 and the packages pheatmap v1.0.12,
pcaMethods v1.78 and genefilter v1.68. Differential expression analysis with edgeR v3.28 used the quasi-likelihood negative binomial generalized log-linear model (GLM) functions provided by the package. False discovery
rate (FDR) correction was performed to adjust for multiple testing, and a cut-off of FDR < 5% was applied.

Target network analysis. miRNA target network analyses and genes ontology enrichments analyses
(KEGG and Reactome) were conducted using miRNet (www.mirnet.ca).

Cell lines and cell culture. The human lung cancer cell line A549 were grown in Dulbecco’s Modified Eagle
Medium (DMEM, 11965-092), with L-Glutamine, and high glucose supplemented with 10% FBS. Cells were
grown in the nutrient medium as suggested by ATCC. Cells were incubated in a humidified incubator with 5%
CO2 at 37 °C. H1975 cells were grown in ATCC-formulated RPMI-1640 Medium (ATCC, Cat number 30-2001),
with 10% FBS (fetal bovine serum) at 37 C, 5% CO2.
Peripheral blood mononuclear cells (PBMC) isolation. 10 mL of blood from healthy individual was

collected into EDTA coated anti-coagulant vacutainer tubes (BD Biosciences #367899). Transferred onto 50 mL
sterile 50 mL centrifuge tube and added equal volume with of ice cold DPBS pH 7.4 and gently mix by inversion.
Using transfer pipette, carefully transferred diluted blood to sterile centrifuge tube containing 10 mL of FicollPaque plus (Amersham #17144003) then centrifuge at 2000 rpm for 25 min. after centrifuged from the fractionated phases, carefully collect the PBMCs fraction between ficol-paque and plasma layer. Collected PBMCs
washed with ice cold PBS and centrifuge at 1700 rpm for 10 min. pellet re-suspended with 2 ml of Pharm Lyse
lysing buffer (Biosciences #555899), mix well incubate at 37 °C for 4 min and adjust volume with PBS to 50 mL
and proceed with centrifuge at 1700 rpm for 10 min. PBMC pellet re suspend in PBS with 1 × 106 cells/mL for
further experimental purpose.

EV/PBMC supernatant transfer experiments. Isolated human PBMCs were seeded and grown in 6

well culture dish with hybridoma-(SFM) serum free medium (Gibco #12045076). PBMCs were treated with
patient EVs under serum free conditions for 24 h. After incubation cell free PBMC or EV/PBMC conditioned
media were collected and used for culturing A549 cells. After 24 h A549 cells were collected for cell counting or
lysed for Western blotting.

Western blotting.

Extracellular vesicles (EV). EV pellets were dissolved in 100 ul of modified lysis buffer
(20 mM Tris–HCl pH-7.5, 150 mM NaCl, 1 mM N
 a2EDTA, 1 mM EGTA, 1%TritonX-100, 2.5 mM sodium
pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4, 1 μg/mL leupeptin). Samples were treated with 10%
glycerol, 1 M urea, 0.1% SDS, and loading buffer before SDS-PAGE. Gels were transferred onto PVDF membranes and stained with primary antibodies against CD-9 (1:1000, Millipore #CBL162), CD-63 (1:1000, Molecular probes #A15712), CD-81 (1:1000, BioLegend #349561), and flotillin (1:1000, Santa Cruz #74566). Secondary
antibodies were anti-mouse horseradish peroxidase (1:10,000, Invitrogen #31430). Protein bands were detected
using the Pierce ECL Chemiluminescence kit western (Thermo Fisher #32106) and the ChemiDoc™ Imaging
System, Bio-Rad Laboratories Inc.
EV‑treated A549 cells. A549 cells were cultured with similar loads of EV derived either from high-risk controls
or confirmed lung cancer patients. Lysates were prepared in lysis buffer (20 mM Tris–HCl pH-7.5, 150 mM
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NaCl, 1 mM N
 a2 EDTA, 1 mM EGTA, 1%TritonX-100) and processed for Western blotting. Blots were stained
against β-catenin to determine WNT signaling levels and GAPDH as a loading control (1:1000, Cell signaling #5174S). Secondary horseradish peroxidase (HRP) antibodies were obtained from Invitrogen. Pierce ECL
Chemiluminescence kit (Thermo Fisher scientific #32106) and the ChemiDoc Imaging System (Bio-Rad) were
used to detect protein bands.
A549 cells were washed with PBS and lysed in a lysis buffer (20 mM Tris–HCl pH-7.5, 150 mM, NaCl,
1 mM Na2EDTA, 1 mM EGTA, 1%Triton, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM
Na3VO4, 1 μg/mL leupeptin) supplemented with protease and a phosphatase inhibitor cocktail (Cell Signaling
#9803S). Proteins were electrophoresed on SDS-PAGE using 4–20% Mini-PROTEAN® TGX™ precast gel (Biorad
#456-1094), transferred onto methanol pretreated PVDF membrane. PVDF membranes were probed overnight
with mouse anti β-catenin (DSHB, #PY489), mouse anti-mTOR (1:1000, Santa Cruz, #517464), mouse anti
phosphor-mTOR (1:1000, Santa Cruz, #293089), and mouse anti-GAPDH (DSHB, #2G7) at 4 °C. Membranes
were incubated with anti-rabbit mouse horseradish peroxidase (HRP) (1:5000, #31460, Invitrogen). Primary or
secondary antibodies were diluted in 5% BSA-TBST. Anti-mouse horseradish peroxidase (HRP) (1:5000, Invitrogen #31430), anti-rabbit horseradish peroxidase (HRP) (1:5000, Invitrogen #31460) used to develop respective
blots. Membranes were developed using Pierce ECL western blotting substrate (Thermo Fisher scientific #32106)
and imaged on ChemiDoc™ MP Imaging System, Bio-Rad Laboratories Inc.
H1975 cells. H1975 cells were lysed in 1 × RIPA buffer (Thermofisher #89900) containing 1 × Halt™ Protease
Inhibitor Cocktail (Thermofisher #78425). Proteins were separated on a 4–12% Bis–Tris gel (Invitrogen, #
NP0321) and transferred to PVDF membranes. Membranes were incubated with primary antibodies against
AKT (1:1000, cell signaling #9272) or phospho-AKT (1:5000, Proteintech #66444-1-Ig) or GAPDH (Sigma
#G8795) overnight at 4 °C. Secondary antibodies were purchased from Cell Signaling (#7076). Blots were developed with Immobilon Western Chemiluminescence Kit (Millipore, #WBKLS0500).
miRNA Transfections and Osimertinib treatments miRNA stock was prepared by suspending in RNAse-free
water. Cells were seeded such that they were 70–80% confluent at the time of transfection. Cells were allowed to
adhere for 24 h and then transfected with 25 nM of miRNA inhibitors against hsa-miR184 (Sigma #HSTUD0282),
hsa-miR22-3p (Sigma #HSTUD0393) or 100 nM of hsa-let7b-5p miRNA mimic (Sigma c#HMI0007) using
Lipofectamine 3000 (Invitrogen #L3000001). Osimertinib (100 nM) was added an hour after transfection to cells.
Cells were allowed to incubate with transfection mix for 24 h at 37 °C, 5% CO2 and then washed with 1 × PBS
and trypsinized to be used for cell count and Western blotting.

cDNA synthesis and qRT‑PCR. cDNA synthesis was carried out using the miRCURY LNA RT Kit (Qia-

gen #339340) from human purified EVs or plasma RNA (10 ng) according to manufacturer’s instructions. The
synthesized CDNA diluted in nuclease free water and stored until further use at − 80 °C as per the kit instructions. Quantitative polymerase chain reaction was conducted using miRCURY LNA miRNA SYBR PCR kit
(Qiagen #339345) as per manufacturer’s instruction on BioRad CFX96™ System in 96-well plates in 3–6 repeats.
A two-step thermal cycling protocol i.e., 95 °C for 2 min followed by 40 cycles at 95 °C for 10 s and 56 °C for
60 s, was used. A no-reverse transcriptase (NRT) and no-template control (NTC) were included in each reaction
to check for primer specificity and any non-specific amplification. miRNA targets include miRNA-184 (Qiagen
#YP00204601), miRNA-21-5p (Qiagen #YP00204230), Let-7b-5p (Qiagen #YP00204750), miRNA 22-3p (Qiagen #YP00204606). The expression levels of each miRNA target were normalized to calibrators U6-snRNA or
GAPDH. Fold changed of miRNA was calculated by ΔΔCt and 2 −ΔΔCt method. ΔCt was calculated by subtracting
the average of Ct values of calibrator from Ct values of target miRNA. ΔΔCt was computed by subtracting ΔCt
of the screening control from ΔCt of RADS IV group.

Patient data analysis. MicroRNA expression (miRNAseq) and clinical data from Lung adenocarcinoma
(LUAD) were collected from the publicly accessible TCGA database using the Bioconductor tool TCGA Biolinks
RTCGA R packages. The “surv_cutpoint” function of the “survminer” R package was used to identify high versus low expressing patients’ samples for survival analysis. Survminer uses selected rank statistics to determine
the optimal cut-point of a continuous variable in an unbiased manner. Kaplan–Meier (KM) survival plots and
related statistics were generated using the Survival R package (Supplemental Information 2).
Leave‑one‑out cross validation (LOOCV) analyses. We evaluated the robustness of the three predic-

tor microRNAs (let-7b-5p, miR-184, miR-22-3p) for the binary outcome cancer-free versus confirmed cases.
We had complete let-7b-5p, miR-184, and miR-22-3p expression data for 35 samples. 35 regression models were
generated, and each time left out one sample to build the model. The sample that was left out was classified using
the model generated from the remaining 34 samples. We then compared in how many instances the prediction
agreed with the actual outcome. The details of the LOOCV analysis and the related R-code are included in Supplemental Table 4.

Data availability

All data will be made available upon reasonable request.
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